872 related articles for article (PubMed ID: 9839089)
1. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
[TBL] [Abstract][Full Text] [Related]
3. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
VandenBrink BM; Isoherranen N
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
[TBL] [Abstract][Full Text] [Related]
4. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
5. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.
Tanaka E
J Clin Pharm Ther; 1998 Dec; 23(6):403-16. PubMed ID: 10048501
[TBL] [Abstract][Full Text] [Related]
6. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.
Bertz RJ; Granneman GR
Clin Pharmacokinet; 1997 Mar; 32(3):210-58. PubMed ID: 9084960
[TBL] [Abstract][Full Text] [Related]
7. Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors.
Naritomi Y; Teramura Y; Terashita S; Kagayama A
Drug Metab Pharmacokinet; 2004 Feb; 19(1):55-61. PubMed ID: 15499170
[TBL] [Abstract][Full Text] [Related]
8. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
Murray M
Int J Mol Med; 1999 Mar; 3(3):227-38. PubMed ID: 10028046
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450-mediated metabolism in the human gut wall.
Thelen K; Dressman JB
J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
[TBL] [Abstract][Full Text] [Related]
12. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.
Walker DK; Alabaster CT; Congrave GS; Hargreaves MB; Hyland R; Jones BC; Reed LJ; Smith DA
Drug Metab Dispos; 1996 Apr; 24(4):447-55. PubMed ID: 8801060
[TBL] [Abstract][Full Text] [Related]
13. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.
Donato MT; Castell JV
Clin Pharmacokinet; 2003; 42(2):153-78. PubMed ID: 12537515
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P; Nagini S
Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450s in the development of target-based anticancer drugs.
Purnapatre K; Khattar SK; Saini KS
Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Fontana E; Dansette PM; Poli SM
Curr Drug Metab; 2005 Oct; 6(5):413-54. PubMed ID: 16248836
[TBL] [Abstract][Full Text] [Related]
17. Enzyme kinetics for clinically relevant CYP inhibition.
Zhang ZY; Wong YN
Curr Drug Metab; 2005 Jun; 6(3):241-57. PubMed ID: 15975042
[TBL] [Abstract][Full Text] [Related]
18. Interactions of herbs with cytochrome P450.
Zhou S; Gao Y; Jiang W; Huang M; Xu A; Paxton JW
Drug Metab Rev; 2003 Feb; 35(1):35-98. PubMed ID: 12635815
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
Kumar G; Lau H; Laskin O
Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition.
Zheng YF; Bae SH; Choi EJ; Park JB; Kim SO; Jang MJ; Park GH; Shin WG; Oh E; Bae SK
Food Chem Toxicol; 2014 Jun; 68():117-27. PubMed ID: 24632066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
